A Phase 2 interventional study of Brexpiprazole and Placebo in Borderline Personality Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 77 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-18.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.
Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 7th largest by enrollment of the 71 interventional ones that give a count, is one of 3 that started in 2019, is one of 16 in phase 2, and was the 46th registered.
278 studies on the registry are indexed under Borderline Personality Disorder; 69 are open to participants now.
Browse Borderline Personality Disorder studies →15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 22–65
Mclean Hospital · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–60
University of California, Los Angeles · Sites in United States
Ages 18–65
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Borderline Personality Disorder studies recruiting now, 18 (38%) set no upper age limit and 29 (60%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 6 · Phase 4 6
First in 1997; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 70 across 221 interventional studies indexed under Borderline Personality Disorder.
Median enrollment 56 across the 71 interventional studies, 48 across the 7 observational. Of the 57 that completed or were terminated, 22 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 81 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 2 studies filed under Borderline Personality Disorder — fewer than ten, so there is no comparison to draw.
7 of the studies in Borderline Personality Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04870255Stanford UniversityTreatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS | 2026-12 |
| NCT05651295Matthew Southward, PhDA Precision Medicine Approach to Target Engagement for Emotion Regulation | 2026-12-31 |
| NCT06683014Yale UniversityMDMA in Borderline Personality Disorder | 2027-06 |
| NCT07460947Mclean HospitalA Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder | 2027-06 |
| NCT06772831Icahn School of Medicine at Mount SinaiCognitive Reappraisal Training for Borderline Personality (BPD) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Borderline Personality Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants diagnosed with BPD to provide a pharmacological treatment for BPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who fulfill the following criteria related to suicide and/or suicidal ideation are excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brexpiprazole, 2-3 milligrams per day (mg/day) tablets, orally, up to Week 12 during the treatment phase.
Drug: Brexpiprazole
Participants received brexpiprazole-matching placebo tablets, orally, up to Week 12 during the treatment phase.
Other: Placebo
Tablet
Also known as: Rexulti®
Tablet
Change From Baseline in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score
The ZAN-BPD is a clinician-administered scale designed to assess severity of disease symptoms in participants with BPD based on clinician rating on 9 criteria. Each of the 9 criteria for BPD was rated on a 5-point anchored rating scale of 0 to 4. These scores were clustered into 4 sector scores (akin to domains) and a total score. The 4 sector scores added up to provide the overall total score for the ZAN-BPD, which ranged from 0 to 36. A higher score represented a higher severity of disease symptoms. Mixed model repeated measures = MMRM, antidepressant therapy = ADT.
Time frame: Baseline (Day 0) to Week 10
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score
The severity of illness for each participant was rated using the CGI-S. CGI-S is an observer-rated scale with a total score range of 0 to 7 where a higher score represented a worse outcome. The response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline (Day 0) to Week 10
Change From Baseline in the Patient's Global Impression of Severity (PGI-S)
PGI-S is a 7-point single-item self-report scale for the participant to rate the severity of symptoms of BPD ranging from 0 to 7 where 1 denoted no symptoms and 7 denoted very severe.
Time frame: Baseline (Day 0), Weeks 2, 4, 6, 8, 10 and 12
Patient's Global Impression of Change (PGI-C) Scale Score
A 7-point single-item self-report scale depicting a participant's rating of overall change in their condition since starting trial medication. Participants answered the question: "Since starting study medication, how much have their symptoms of Borderline Personality Disorder changed?" with a score ranging from 1 to 7 where 1 denoted very much improved and 7 denoted very much worse.
Time frame: Weeks 2, 4, 6, 8,10 and 12
Clinical Global Impression - Improvement (CGI-I) Scale Score
Participant's condition was assessed using CGI-I scale. CGI-I is an observer-rated scale with a total score of 0 to 7 and a higher score represents a worse outcome. The score included the following response choices: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Weeks 2, 4, 6, 8, 10 and 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE that started after start of study treatment.
Time frame: From Baseline (Day 0) to 21 days after last dose (Up to Week 15)
Number of Participants With Potentially Clinically Relevant Laboratory Test Values
Laboratory parameters included hematology(Hem), serum chemistry(Che) and urinalysis(Uri). Criterion:Che-Alkaline Phosphatase (Units/liter \[U/L\]):≥3 x ULN, Aspartate Aminotransferase (U/L):≥3 x ULN,Bilirubin (mg/deciliter\[dL\]):≥2.0,Cholesterol(Cho);Cho,fasting(mg/dl):≥240,Creatine Kinase(U/L):≥3 x ULN, Creatinine(mg/dL):≥2.0,Glucose (Glu);Glu,fasting(mg/dL):100,High Density Lipoprotein (HDL) Cho (mg/dL):Male (M) \< 40or Female (F) \<50, Low Density Lipoprotein (LDL) Cho(mg/dL):≥160,Prolactin (nanograms/milliliter \[ng/mL\]):\>1 x ULN,Triglyceride (mg/dL):≥150,Urate(mg/dL): M ≥10.5 or F ≥8.5,Urea Nitrogen (mg/dL):≥30,Hem-Eosinophils (Eosi) (10\^9 L):≥10%,Hematocrit (%): M ≤37% and ≥3 percentage (per) point decrease from baseline or F≤32% and ≥3per point decrease from baseline, Hemaglobin(gram per deciliter \[g/dL\]):M ≤11.5 or F ≤9.5,Leukocytes(10\^9/L):≤2.8 x10\^3/uL,≤16.0 x10\^3/uL,Platelets(10\^9/L):≤75 x10\^3/ uL,≥700 x10\^3/uL,Uri-Glu,urine; Protein,urine:Increase of ≥2U.
Time frame: From first dose of study drug up to Week 12
Number of Participants With Potential Clinical Relevant Laboratory Test Values - Prolactin
New onset (\> 1 x upper limit of normal {ULN}, \> 2 x ULN, 3 X ULN) prolactin means a participant who attains a categorical change during treatment phase but not at baseline. Only those categories with at least one participant with event are reported.
Time frame: Week 12
Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs
Vital Signs included orthostatic hypotension, heart rate (HR), systolic and diastolic blood pressure (bp), and weight. Potential clinical relevance criterion: Orthostatic Hypotension:\>= 20 millimeters of mercury (mmhg) decrease in systolic bp and \>= 25 beats per minute (bpm) increase in HR from supine to standing; HR Standing (bpm):\< 50 and decrease \>= 15,\> 120 and increase \>= 15; HR Supine (bpm): \< 50 and decrease \>= 15,\>120 and increase \>= 15; Systolic BP Standing (mmhg):\< 90 and decrease \>=20,\> 180 and increase \>= 20; Systolic BP Supine (mmhg):\< 90 and decrease \>= 20, \>180 and increase \>= 20; Diastolic BP Standing (mmHg): \< 50 and decrease \>= 15,\> 105 and increase \>= 15; Diastolic BP Supine (mmHg):\< 50 and decrease \>= 15, \> 105 and increase \>= 15; Weight (kilograms\[kg\]): Decrease or increase \>= 7%. Only those categories with at least one participant with event are reported.
Time frame: From first dose of study drug up to Week 12
Change From Baseline in Body Weight
Time frame: Baseline (Day 0), Weeks 2, 4, 6, 8, 10, and 12
Change From Baseline in Waist Circumference
Time frame: Baseline (Screening: Day -21 to Day -1), Week 12
Change From Baseline in Body Mass Index (BMI)
BMI is defined as weight in kilograms divided by the square of height in meters.
Time frame: Baseline (Day 0), Weeks 2, 4, 6, 8, 10, and 12
Number of Participants With Potentially Clinically Relevant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters
ECG parameters analyzed included rhythm, conduction and ST/T morphology. Potential clinical relevance criterion: Rhythm- Supraventricular Premature Beat: not present at baseline and present post baseline, Ventricular Premature Beat: not present at baseline and present post baseline, Conduction- Right Bundle Branch Block: not present at baseline and present post baseline, ST/T Morphology- Symmetrical (Sym) T-Wave Inversion: not present at baseline and present post baseline. Only those categories with at least one participant with event are reported.
Time frame: Week 12
Change From Baseline in Simpson-Angus Scale (SAS) Total Score
The SAS consisted of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item was rated on a 5-point scale, with a score of zero representing the absence of symptoms and a score of 4 representing a severe condition. The SAS total score was the sum of the scores for all 10 items and ranged from 0 to 40. Higher scores indicated worst outcome.
Time frame: Baseline (Day 0), Week 6 and 12
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
AIMS assessment consisted of 10 items describing symptoms of dyskinesia (muscles of facial expression, lips and perioral area, jaw, tongue, upper extremities, lower extremities, neck/shoulders/hips, overall movement severity, incapacitation, participant awareness). Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while participant was at rest (e.g., in waiting room), and study physician would make global judgments on participant's dyskinesia's (items 8 through 10). Each item was rated on 5-point scale of severity from 0 (none) to 4 (severe) and assessment of problems with teeth or dentures (yes = 1, no = 0) and if the participant normally wears dentures (yes = 1, no = 0). Total score ranged from 0 to 42. Higher scores indicated worst outcome.
Time frame: Baseline (Day 0), Weeks 6 and 12
Change From Baseline in Barnes Akathisia Rating Scale (BARS): Global Clinical Assessment of Akathisia Score
The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The global clinical evaluation was made on a 6-point scale, with zero representing absence of symptoms and a score of 5 representing severe akathisia.
Time frame: Baseline (Day 0), Weeks 6 and 12
Number of Participants With Suicidal Behavior and Suicidal Ideation As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Suicidality was monitored using the C-SSRS. Suicidality was defined as at least one occurrence of suicidal ideation (including wish to be dead, non-specific suicidal thought, suicidal ideation-no intent, ideation with intent, no plan, ideation with plan/intent) or at least one occurrence of suicidal behavior (actual attempt, non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts/behavior, suicidal behavior) for the assessment period.
Time frame: Baseline (Day 0) to Week 12
Participants were enrolled in the study at 62 study centers in the United States, Spain, and Ukraine from 17 October 2019 to 27 Jun 2021.
| Milestone | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Started | 159 | 165 |
| Safety population | 157 | 165 |
| Full analysis set (fas) for enriched participants | 112 | 111 |
| Completed | 112 | 127 |
| Not completed | 47 | 38 |
| Withdrew: Adverse event | 19 | 7 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 13 | 11 |
| Withdrew: Non-compliance with study drug | 1 | 3 |
| Withdrew: Protocol deviation | 1 | 1 |
| Withdrew: Withdrawal by participant | 13 | 15 |
The ZAN-BPD is a clinician-administered scale designed to assess severity of disease symptoms in participants with BPD based on clinician rating on 9 criteria. Each of the 9 criteria for BPD was rated on a 5-point anchored rating scale of 0 to 4. These scores were clustered into 4 sector scores (akin to domains) and a total score. The 4 sector scores added up to provide the overall total score for the ZAN-BPD, which ranged from 0 to 36. A higher score represented a higher severity of disease symptoms. Mixed model repeated measures = MMRM, antidepressant therapy = ADT.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Change From Baseline in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score | -7.27 ± 0.80 | -6.25 ± 0.76 |
The severity of illness for each participant was rated using the CGI-S. CGI-S is an observer-rated scale with a total score range of 0 to 7 where a higher score represented a worse outcome. The response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score | -1.13 ± 0.14 | -1.09 ± 0.14 |
PGI-S is a 7-point single-item self-report scale for the participant to rate the severity of symptoms of BPD ranging from 0 to 7 where 1 denoted no symptoms and 7 denoted very severe.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Change from Baseline at Week 2 | -0.33 ± 0.12 | -0.27 ± 0.12 |
| Change from Baseline at Week 4 | -0.60 ± 0.15 | -0.35 ± 0.14 |
| Change from Baseline at Week 6 | -0.91 ± 0.15 | -0.72 ± 0.14 |
| Change from Baseline at Week 8 | -0.99 ± 0.14 | -0.69 ± 0.14 |
| Change from Baseline at Week 10 | -0.90 ± 0.15 | -0.79 ± 0.14 |
| Change from Baseline at Week 12 | -1.00 ± 0.16 | -0.86 ± 0.15 |
A 7-point single-item self-report scale depicting a participant's rating of overall change in their condition since starting trial medication. Participants answered the question: "Since starting study medication, how much have their symptoms of Borderline Personality Disorder changed?" with a score ranging from 1 to 7 where 1 denoted very much improved and 7 denoted very much worse.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Week 2 | 3.38 ± 0.89 | 3.30 ± 0.93 |
| Week 4 | 3.23 ± 1.26 | 3.25 ± 1.22 |
| Week 6 | 2.94 ± 1.14 | 3.15 ± 1.11 |
| Week 8 | 2.94 ± 1.10 | 3.11 ± 1.12 |
| Week 10 | 2.89 ± 1.26 | 2.97 ± 1.20 |
| Week 12 | 2.88 ± 1.19 | 2.96 ± 1.14 |
Participant's condition was assessed using CGI-I scale. CGI-I is an observer-rated scale with a total score of 0 to 7 and a higher score represents a worse outcome. The score included the following response choices: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Week 2 | 2.99 ± 0.96 | 2.99 ± 0.97 |
| Week 4 | 2.89 ± 1.04 | 3.00 ± 1.20 |
| Week 6 | 2.62 ± 1.05 | 2.77 ± 1.21 |
| Week 8 | 2.39 ± 1.06 | 2.79 ± 1.26 |
| Week 10 | 2.45 ± 1.18 | 2.61 ± 1.20 |
| Week 12 | 2.37 ± 1.19 | 2.65 ± 1.17 |
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE that started after start of study treatment.
| Participants | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 95 | 79 |
Laboratory parameters included hematology(Hem), serum chemistry(Che) and urinalysis(Uri). Criterion:Che-Alkaline Phosphatase (Units/liter \[U/L\]):≥3 x ULN, Aspartate Aminotransferase (U/L):≥3 x ULN,Bilirubin (mg/deciliter\[dL\]):≥2.0,Cholesterol(Cho);Cho,fasting(mg/dl):≥240,Creatine Kinase(U/L):≥3 x ULN, Creatinine(mg/dL):≥2.0,Glucose (Glu);Glu,fasting(mg/dL):100,High Density Lipoprotein (HDL) Cho (mg/dL):Male (M) \< 40or Female (F) \<50, Low Density Lipoprotein (LDL) Cho(mg/dL):≥160,Prolactin (nanograms/milliliter \[ng/mL\]):\>1 x ULN,Triglyceride (mg/dL):≥150,Urate(mg/dL): M ≥10.5 or F ≥8.5,Urea Nitrogen (mg/dL):≥30,Hem-Eosinophils (Eosi) (10\^9 L):≥10%,Hematocrit (%): M ≤37% and ≥3 percentage (per) point decrease from baseline or F≤32% and ≥3per point decrease from baseline, Hemaglobin(gram per deciliter \[g/dL\]):M ≤11.5 or F ≤9.5,Leukocytes(10\^9/L):≤2.8 x10\^3/uL,≤16.0 x10\^3/uL,Platelets(10\^9/L):≤75 x10\^3/ uL,≥700 x10\^3/uL,Uri-Glu,urine; Protein,urine:Increase of ≥2U.
| Participants | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Che: Alkaline Phosphatase, High | 1 | 0 |
| Che: Aspartate Aminotransferase, High | 1 | 0 |
| Che: Bilirubin, High | 0 | 2 |
| Che: Cho, High | 2 | 4 |
| Che: Cho Fasting, High | 13 | 7 |
| Che: Creatine Kinase, High | 4 | 3 |
| Che: Creatinine, High | 1 | 0 |
| Che: Glu Fasting, High | 29 | 30 |
| Che: HDL Cho, Fasting, Low | 46 | 42 |
| Che: Low LDL Cho, High | 3 | 4 |
| Che: LDL Cholesterol, Fasting, High | 11 | 8 |
| Che: Prolactin, High | 41 | 7 |
| Che: Triglyceride, Fasting, High | 35 | 25 |
| Che: Urate, High | 1 | 0 |
| Che: Urea Nitrogen, High | 2 | 0 |
| Hem: Eosi/Leukocytes Ratio, High | 4 | 2 |
| Hem: Hematocrit, Low | 2 | 4 |
| Hem: Hemoglobin, Low | 2 | 2 |
| Hematology: Leukocytes, Low | 0 | 1 |
| Hem: Leukocytes, High | 2 | 0 |
| Hem: Platelets, Low | 0 | 2 |
| Uri: Glu, Urine, High | 0 | 1 |
| Uri: Protein, Urine, High | 1 | 0 |
New onset (\> 1 x upper limit of normal {ULN}, \> 2 x ULN, 3 X ULN) prolactin means a participant who attains a categorical change during treatment phase but not at baseline. Only those categories with at least one participant with event are reported.
| Participants | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Prolactin: >1 x ULN | 37 | 4 |
| Prolactin: >2 x ULN | 1 | 1 |
Vital Signs included orthostatic hypotension, heart rate (HR), systolic and diastolic blood pressure (bp), and weight. Potential clinical relevance criterion: Orthostatic Hypotension:\>= 20 millimeters of mercury (mmhg) decrease in systolic bp and \>= 25 beats per minute (bpm) increase in HR from supine to standing; HR Standing (bpm):\< 50 and decrease \>= 15,\> 120 and increase \>= 15; HR Supine (bpm): \< 50 and decrease \>= 15,\>120 and increase \>= 15; Systolic BP Standing (mmhg):\< 90 and decrease \>=20,\> 180 and increase \>= 20; Systolic BP Supine (mmhg):\< 90 and decrease \>= 20, \>180 and increase \>= 20; Diastolic BP Standing (mmHg): \< 50 and decrease \>= 15,\> 105 and increase \>= 15; Diastolic BP Supine (mmHg):\< 50 and decrease \>= 15, \> 105 and increase \>= 15; Weight (kilograms\[kg\]): Decrease or increase \>= 7%. Only those categories with at least one participant with event are reported.
| Participants | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Orthostatic Hypotension: Low | 0 | 1 |
| Heart Rate Standing, High | 2 | 0 |
| Heart Rate Supine, Low | 1 | 1 |
| Systolic Blood Pressure Standing, Low | 1 | 1 |
| Systolic Blood Pressure Supine, Low | 1 | 0 |
| Weight, Increase | 5 | 3 |
| Weight, Decrease | 25 | 12 |
| kilogram (kg) | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Baseline (Day 0) | 78.60 ± 22.15 | 78.85 ± 22.33 |
| Change From Baseline at Week 2 | 0.27 ± 1.15 | 0.09 ± 1.62 |
| Change From Baseline at Week 4 | 1.05 ± 1.92 | -0.05 ± 2.02 |
| Change From Baseline at Week 6 | 1.39 ± 2.25 | 0.20 ± 2.21 |
| Change From Baseline at Week 8 | 1.55 ± 2.75 | -0.03 ± 2.41 |
| Change From Baseline at Week 10 | 2.09 ± 2.96 | 0.37 ± 2.72 |
| Change From Baseline at Week 12 | 1.74 ± 3.09 | 0.30 ± 2.75 |
| centimeter | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Baseline (Screening: Day -21 to Day -1) | 89.74 ± 17.54 | 90.01 ± 17.25 |
| Change from Baseline at Week 12 | 1.07 ± 5.23 | -0.32 ± 5.76 |
BMI is defined as weight in kilograms divided by the square of height in meters.
| kilograms per square meter (kg/m^2) | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Baseline (Day 0) | 27.35 ± 7.49 | 28.52 ± 7.69 |
| Change From Baseline at Week 2 | 0.09 ± 0.42 | 0.05 ± 0.62 |
| Change From Baseline at Week 4 | 0.38 ± 0.68 | -0.00 ± 0.75 |
| Change From Baseline at Week 6 | 0.50 ± 0.81 | 0.09 ± 0.83 |
| Change From Baseline at Week 8 | 0.57 ± 1.01 | 0.00 ± 0.89 |
| Change From Baseline at Week 10 | 0.76 ± 1.10 | 0.15 ± 1.00 |
| Change From Baseline at Week 12 | 0.64 ± 1.17 | 0.13 ± 1.01 |
ECG parameters analyzed included rhythm, conduction and ST/T morphology. Potential clinical relevance criterion: Rhythm- Supraventricular Premature Beat: not present at baseline and present post baseline, Ventricular Premature Beat: not present at baseline and present post baseline, Conduction- Right Bundle Branch Block: not present at baseline and present post baseline, ST/T Morphology- Symmetrical (Sym) T-Wave Inversion: not present at baseline and present post baseline. Only those categories with at least one participant with event are reported.
| Participants | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Rhythm: Supraventricular Premature Beat | 0 | 1 |
| Rhythm: Ventricular Premature Beat | 1 | 0 |
| Conduction: Right Bundle Branch Block | 1 | 0 |
| ST/T Morphology: Symmetrical T-Wave Inversion | 0 | 1 |
The SAS consisted of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item was rated on a 5-point scale, with a score of zero representing the absence of symptoms and a score of 4 representing a severe condition. The SAS total score was the sum of the scores for all 10 items and ranged from 0 to 40. Higher scores indicated worst outcome.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Baseline (Day 0) | 0.18 ± 0.65 | 0.24 ± 0.92 |
| Change from Baseline at Week 6 | 0.04 ± 0.76 | -0.08 ± 0.55 |
| Change from Baseline at Week 12 | 0.04 ± 0.88 | -0.05 ± 0.63 |
AIMS assessment consisted of 10 items describing symptoms of dyskinesia (muscles of facial expression, lips and perioral area, jaw, tongue, upper extremities, lower extremities, neck/shoulders/hips, overall movement severity, incapacitation, participant awareness). Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while participant was at rest (e.g., in waiting room), and study physician would make global judgments on participant's dyskinesia's (items 8 through 10). Each item was rated on 5-point scale of severity from 0 (none) to 4 (severe) and assessment of problems with teeth or dentures (yes = 1, no = 0) and if the participant normally wears dentures (yes = 1, no = 0). Total score ranged from 0 to 42. Higher scores indicated worst outcome.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Baseline (Day 0) | 0.03 ± 0.20 | 0.04 ± 0.42 |
| Change from Baseline at Week 6 | -0.02 ± 0.25 | 0.09 ± 0.87 |
| Change from Baseline at Week 12 | -0.02 ± 0.27 | 0.07 ± 0.73 |
The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The global clinical evaluation was made on a 6-point scale, with zero representing absence of symptoms and a score of 5 representing severe akathisia.
| score on a scale | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Baseline (Day 0) | 0.08 ± 0.27 | 0.12 ± 0.40 |
| Change from Baseline at Week 6 | 0.15 ± 0.59 | -0.04 ± 0.37 |
| Change from Baseline at Week 12 | 0.06 ± 0.53 | -0.05 ± 0.33 |
Suicidality was monitored using the C-SSRS. Suicidality was defined as at least one occurrence of suicidal ideation (including wish to be dead, non-specific suicidal thought, suicidal ideation-no intent, ideation with intent, no plan, ideation with plan/intent) or at least one occurrence of suicidal behavior (actual attempt, non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts/behavior, suicidal behavior) for the assessment period.
| Participants | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Suicidal Behavior | 42 | 29 |
| Suicidal Ideation | 78 | 70 |
Collected over From Baseline (Day 0) to 21 days after last dose (up to Week 15). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 2-3 Milligrams Per Day | 0/157 (0%) | 5/157 (3.2%) | 69/157 (43.9%) |
| Placebo | 0/165 (0%) | 2/165 (1.2%) | 45/165 (27.3%) |
| Event | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| Suicide AttemptPsychiatric disorders | 2/157 | 0/165 |
| Cerebrovascular AccidentNervous system disorders | 1/157 | 0/165 |
| Major DepressionPsychiatric disorders | 1/157 | 0/165 |
| Panic AttackPsychiatric disorders | 1/157 | 0/165 |
| GastritisGastrointestinal disorders | 0/157 | 1/165 |
| PneumoniaInfections and infestations | 0/157 | 1/165 |
| DissociationPsychiatric disorders | 0/157 | 1/165 |
| Event | Brexpiprazole 2-3 Milligrams Per Day | Placebo |
|---|---|---|
| AkathisiaNervous system disorders | 22/157 | 2/165 |
| InsomniaPsychiatric disorders | 15/157 | 10/165 |
| AnxietyPsychiatric disorders | 13/157 | 9/165 |
| FatigueGeneral disorders | 12/157 | 6/165 |
| HeadacheNervous system disorders | 8/157 | 12/165 |
| Weight IncreasedInvestigations | 10/157 | 4/165 |
| RestlessnessPsychiatric disorders | 10/157 | 2/165 |
| Increased AppetiteMetabolism and nutrition disorders | 8/157 | 4/165 |
| SomnolenceNervous system disorders | 8/157 | 5/165 |
Randomized population included all participants who were randomized to receive brexpiprazole or matching placebo in the treatment phase.
| Age, Continuous(years) | Brexpiprazole 2 to 3 Milligrams Per Day | Placebo | Total |
|---|---|---|---|
| Mean | 32.0 ± 10.6 | 31.0 ± 10.9 | 31.5 ± 10.7 |
| Sex: Female, Male(Participants) | Brexpiprazole 2 to 3 Milligrams Per Day | Placebo | Total |
|---|---|---|---|
| Female | 129 | 137 | 266 |
| Male | 30 | 28 | 58 |
| Race (NIH/OMB)(Participants) | Brexpiprazole 2 to 3 Milligrams Per Day | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 3 |
| Asian | 7 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 19 | 22 | 41 |
| White | 123 | 131 | 254 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 9 | 15 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole 2 to 3 Milligrams Per Day | Placebo | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 31 | 33 | 64 |
| Ethnicity — Not Hispanic or Latino | 127 | 131 | 258 |
| Ethnicity — Unknown | 1 | 0 | 1 |
| Ethnicity — Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Oct 2019 to primary completion in Jun 2021, 20 months.
Results were first posted in Jul 2024, 3 years after primary completion. A results delay was requested in Jun 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Borderline Personality Disorder →
Otsuka Pharmaceutical Development & Commercialization, Inc. →